NCT/Study#
NCT04289779 /
GU18-343
A Phase 2 Study Of Cabozantinib In Combination With Atezolizumab As Neoadjuvant Treatment For Muscle-Invasive Bladder Cancer (ABATE)
DISEASE GROUP:
Genito-Urinary
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
